Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 984 of 6351
-
Which therapy works best for kids with MIS-C?
Disease control CompletedIn March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus. Some children were sick enough to require care in the intensive care unit for what came to be kn…
Phase 2/3 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Immunotherapy combo shows promise against tough lung cancer
Disease control OngoingCombination of concomitant Radio-Chemotherapy showed a significant improvement (Takada) of OS and PFS in limited disease SCLC patients. This clinical trial is a prospective, multicenter, randomized, open-label, parallel group phase II investigator initiated trial (ITT) to evaluat…
Phase 2 • Sponsor: Michael Hopp • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for advanced lung cancer: experimental drug DS-1062a takes on standard chemo
Disease control OngoingThis study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New cancer combo aims to shrink Hard-to-Treat tumors
Disease control OngoingThis study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how …
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New device aims to restore heart function in failing hearts
Disease control PausedProspective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Sponsor: Ancora Heart, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Head-to-Head: which biologic works better for tough psoriatic arthritis?
Disease control CompletedThe purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
A genetic roadmap for Parkinson's: testing thousands to unlock clues
Knowledge-focused Recruiting nowDevelopment of a central repository for PD-related genomic data for future research.
Sponsor: Parkinson's Foundation • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
New drug cocktail aims to stall deadly pancreatic cancer
Disease control OngoingThe study researchers think that combining the drugs pembrolizumab and olaparib (POLAR) may help people with this disease because pembrolizumab activates the immune system to fight cancer, and olaparib destroys cancer cells by preventing them from repairing damage to the genetic …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for bladder cancer patients avoiding bladder removal
Disease control OngoingThe purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant h…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New nerve treatment could ease heart failure symptoms
Disease control Recruiting nowThe purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is…
Sponsor: Axon Therapies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo shows promise against hereditary breast cancer
Disease control OngoingThis research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: * Niraparib (Zejula) * Dostarlimab
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can a cancer drug make stem cell transplants safer for myelofibrosis patients?
Disease control OngoingThis phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in patients with primary and secondary myelofibrosis. Donor …
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Promising combo targets hard-to-treat breast cancer
Disease control OngoingDESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Hope for friedreich ataxia: experimental drug vatiquinone put to the test
Disease control CompletedThe primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale \[mFARS\]) and safety of vatiquinone in participants with Friedreich ataxia (FA).
Phase 2/3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for CAH: drug may slash steroid use
Disease control OngoingThis is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind,…
Phase 3 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in cutting COPD attacks for former smokers
Disease control CompletedPrimary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: * Evaluate the efficacy of itepekimab compared with placebo o…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could adding radiation before surgery boost breast cancer treatment?
Disease control OngoingThis research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in…
Phase 2 • Sponsor: Laura M. Spring, MD • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for kidney cancer: drug cocktails aim to shrink tumors
Disease control OngoingSubstudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational a…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New pill targets rare gene fault in advanced cancers
Disease control Recruiting nowPhase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in ph…
Phase 1/2 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Triple-Drug cocktail aims to boost remission in CLL
Disease control OngoingThis study is testing the effectiveness of the study drug combination of acalabrutinib, umbralisib, and ublituximab in participants with Chronic Lymphocytic leukemia (CLL). The names of the study drugs involved in this study are/is: * Acalabrutinib (CALQUENCE®, ACP-196) * Umbra…
Phase 2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC